MedWatch

Nordic venture capital firms expand to listed biotechs in hunt for bargains

Large stock drops for listed biotech companies have piqued the interest of two Nordic investors, one of which is backed by Novo Holdings.

Photo: Spar Nord/PR

Two Nordic early-stage biotech investors are warming to the idea of buying into listed companies that have become too cheap to ignore.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs